AMT-130 has been granted Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as ...

A Belgian study compared exercise performance before and after COVID-19 lockdown measures were swiftly implemented in the country among patients with preexisting pulmonary arterial hypertension (PAH).

A Huntington’s gene therapy by UniQure has made waves after slowing disease progression by 75% in a mid-stage trial. During ...

Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by ...

A home-based strength training program does not improve dyspnea in patients with chronic obstructive lung disease (COPD), but it does improve some functional capacity and helps patients feel better, a ...

T opline data showed that an investigational gene therapy slowed Huntington's disease progression and met its primary endpoint in a pivotal trial, uniQure Biopharma announced Wednesday.